These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
365 related articles for article (PubMed ID: 3032456)
1. Coexpression of MMTV/v-Ha-ras and MMTV/c-myc genes in transgenic mice: synergistic action of oncogenes in vivo. Sinn E; Muller W; Pattengale P; Tepler I; Wallace R; Leder P Cell; 1987 May; 49(4):465-75. PubMed ID: 3032456 [TBL] [Abstract][Full Text] [Related]
2. Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Muller WJ; Sinn E; Pattengale PK; Wallace R; Leder P Cell; 1988 Jul; 54(1):105-15. PubMed ID: 2898299 [TBL] [Abstract][Full Text] [Related]
3. Spontaneous progression of hyperplastic outgrowths of the D1 lineage to mammary tumors: expression of mouse mammary tumor virus and cellular proto-oncogenes. Knepper JE; Kittrell FS; Medina D; Butel JS Mol Carcinog; 1989; 1(4):229-38. PubMed ID: 2551332 [TBL] [Abstract][Full Text] [Related]
4. Differential regulation of cell cycle characteristics and apoptosis in MMTV-myc and MMTV-ras mouse mammary tumors. Hundley JE; Koester SK; Troyer DA; Hilsenbeck SG; Barrington RE; Windle JJ Cancer Res; 1997 Feb; 57(4):600-3. PubMed ID: 9044833 [TBL] [Abstract][Full Text] [Related]
5. A farnesyltransferase inhibitor induces tumor regression in transgenic mice harboring multiple oncogenic mutations by mediating alterations in both cell cycle control and apoptosis. Barrington RE; Subler MA; Rands E; Omer CA; Miller PJ; Hundley JE; Koester SK; Troyer DA; Bearss DJ; Conner MW; Gibbs JB; Hamilton K; Koblan KS; Mosser SD; O'Neill TJ; Schaber MD; Senderak ET; Windle JJ; Oliff A; Kohl NE Mol Cell Biol; 1998 Jan; 18(1):85-92. PubMed ID: 9418856 [TBL] [Abstract][Full Text] [Related]
6. Harderian gland pathology in transgenic mice carrying the MMTV/v-Ha-ras gene. White V; Sinn E; Albert DM Invest Ophthalmol Vis Sci; 1990 Mar; 31(3):577-81. PubMed ID: 2156784 [TBL] [Abstract][Full Text] [Related]
7. Myc/p53 interactions in transgenic mouse mammary development, tumorigenesis and chromosomal instability. McCormack SJ; Weaver Z; Deming S; Natarajan G; Torri J; Johnson MD; Liyanage M; Ried T; Dickson RB Oncogene; 1998 May; 16(21):2755-66. PubMed ID: 9652742 [TBL] [Abstract][Full Text] [Related]
8. Mammary tumorigenesis in C3Hf/Ki mice: examination of germinal mouse mammary tumor viruses and the int-1 and int-2 putative proto-oncogenes. Popko BJ; Pauley RJ Virus Res; 1985 Apr; 2(3):231-43. PubMed ID: 2988229 [TBL] [Abstract][Full Text] [Related]
9. Keratinocyte growth factor induces mammary and prostatic hyperplasia and mammary adenocarcinoma in transgenic mice. Kitsberg DI; Leder P Oncogene; 1996 Dec; 13(12):2507-15. PubMed ID: 9000125 [TBL] [Abstract][Full Text] [Related]
10. Tumorigenesis and male sterility in transgenic mice expressing a MMTV/N-ras oncogene. Mangues R; Seidman I; Pellicer A; Gordon JW Oncogene; 1990 Oct; 5(10):1491-7. PubMed ID: 2174525 [TBL] [Abstract][Full Text] [Related]
11. Expression of an activated Notch-related int-3 transgene interferes with cell differentiation and induces neoplastic transformation in mammary and salivary glands. Jhappan C; Gallahan D; Stahle C; Chu E; Smith GH; Merlino G; Callahan R Genes Dev; 1992 Mar; 6(3):345-55. PubMed ID: 1372276 [TBL] [Abstract][Full Text] [Related]
12. Synergistic interaction of transforming growth factor alpha and c-myc in mouse mammary and salivary gland tumorigenesis. Amundadottir LT; Johnson MD; Merlino G; Smith GH; Dickson RB Cell Growth Differ; 1995 Jun; 6(6):737-48. PubMed ID: 7669729 [TBL] [Abstract][Full Text] [Related]
15. Oncogene expression during progression of mouse mammary tumor cells; activity of a proviral enhancer and the resulting expression of int-2 is influenced by the state of differentiation. Sonnenberg A; van Balen P; Hilgers J; Schuuring E; Nusse R EMBO J; 1987 Jan; 6(1):121-5. PubMed ID: 3034568 [TBL] [Abstract][Full Text] [Related]
16. Chemical effects in transgenic mice bearing oncogenes expressed in mammary tissue. Tennant RW; Rao GN; Russfield A; Seilkop S; Braun AG Carcinogenesis; 1993 Jan; 14(1):29-35. PubMed ID: 8093862 [TBL] [Abstract][Full Text] [Related]
17. Protein-tyrosine phosphatase epsilon. An isoform specifically expressed in mouse mammary tumors initiated by v-Ha-ras OR neu. Elson A; Leder P J Biol Chem; 1995 Nov; 270(44):26116-22. PubMed ID: 7592814 [TBL] [Abstract][Full Text] [Related]
18. Protein tyrosine phosphatase epsilon increases the risk of mammary hyperplasia and mammary tumors in transgenic mice. Elson A Oncogene; 1999 Dec; 18(52):7535-42. PubMed ID: 10602512 [TBL] [Abstract][Full Text] [Related]
19. Mammary tumor development in MMTV-c-myc/MMTV-v-Ha-ras transgenic mice is unaffected by osteopontin deficiency. Feng F; Rittling SR Breast Cancer Res Treat; 2000 Sep; 63(1):71-9. PubMed ID: 11079161 [TBL] [Abstract][Full Text] [Related]
20. Acceleration of mouse mammary tumor virus-induced murine mammary tumorigenesis by a p53 172H transgene: influence of FVB background on tumor latency and identification of novel sites of proviral insertion. Chatterjee G; Rosner A; Han Y; Zelazny ET; Li B; Cardiff RD; Perkins AS Am J Pathol; 2002 Dec; 161(6):2241-53. PubMed ID: 12466138 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]